P/E ratio for CTI BioPharma (CTIC)

P/E ratio history for CTI BioPharma from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Amgen AMGN	23.9	-252.68%	🇺🇸 USA
Bristol-Myers Squibb BMY	12.4	-179.21%	🇺🇸 USA
Incyte INCY	34.6	-320.90%	🇺🇸 USA
Baxter BAX	7.53	-148.04%	🇺🇸 USA
Eli Lilly LLY	171	-1,192.16%	🇺🇸 USA
Teva Pharmaceutical Industries TEVA	-8.76	-44.11%	🇮🇱 Israel
Novartis NVS	31.1	-298.41%	🇨🇭 Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.